Home/Filings/4/0001415889-25-009294
4//SEC Filing

Huang Michael F. 4

Accession 0001415889-25-009294

CIK 0001484565other

Filed

Mar 30, 8:00 PM ET

Accepted

Mar 31, 7:18 PM ET

Size

25.8 KB

Accession

0001415889-25-009294

Insider Transaction Report

Form 4
Period: 2025-03-27
Huang Michael F.
Sr. VP of Clinical Development
Transactions
  • Sale

    Common Stock

    2025-03-27$66.79/sh604$40,34240,425 total
  • Sale

    Common Stock

    2025-03-27$68.79/sh1,444$99,33037,883 total
  • Sale

    Common Stock

    2025-03-27$65.97/sh371$24,47541,029 total
  • Sale

    Common Stock

    2025-03-27$70.73/sh86$6,08336,961 total
  • Sale

    Common Stock

    2025-03-27$71.74/sh125$8,96836,836 total
  • Sale

    Common Stock

    2025-03-27$70.03/sh10,000$700,33036,817 total
  • Sale

    Common Stock

    2025-03-27$67.70/sh1,098$74,33539,327 total
  • Sale

    Common Stock

    2025-03-27$69.84/sh836$58,38437,047 total
  • Sale

    Common Stock

    2025-03-27$72.64/sh19$1,38036,817 total
  • Exercise/Conversion

    Common Stock

    2025-03-27$21.93/sh+10,000$219,30046,817 total
  • Exercise/Conversion

    Employee stock option (right to buy)

    2025-03-2710,000110,000 total
    Exercise: $21.93Exp: 2033-11-08Common Stock (10,000 underlying)
Footnotes (12)
  • [F1]These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs").
  • [F10]This transaction was executed in multiple trades at prices ranging from $72.31 to $72.80. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F11]This transaction was executed in multiple trades at prices ranging from $70.01 to $70.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F12]One-fourth of the shares subject to the option vest on November 1, 2024 and one-forty-eighth of the shares subject to the option shall vest on each one-month anniversary thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date.
  • [F2]This transaction was executed in multiple trades at prices ranging from $65.15 to $66.145. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F3]Certain of these securities are RSUs. Each RSU represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each RSU.
  • [F4]This transaction was executed in multiple trades at prices ranging from $66.24 to $67.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F5]This transaction was executed in multiple trades at prices ranging from $67.24 to $68.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F6]This transaction was executed in multiple trades at prices ranging from $68.24 to $69.225. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F7]This transaction was executed in multiple trades at prices ranging from $69.24 to $70.235. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F8]This transaction was executed in multiple trades at prices ranging from $70.24 to $71.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
  • [F9]This transaction was executed in multiple trades at prices ranging from $71.26 to $72.22. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

Issuer

SOLENO THERAPEUTICS INC

CIK 0001484565

Entity typeother

Related Parties

1
  • filerCIK 0002019992

Filing Metadata

Form type
4
Filed
Mar 30, 8:00 PM ET
Accepted
Mar 31, 7:18 PM ET
Size
25.8 KB